From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Monday's episode, health-care analyst David Williamson takes a look at Novartis (NYSE:NVS)and its announcement that it will be selling off its blood-borne pathogen diagnostics business to the Barcelona-based company Grifols for $1.7 billion. David takes a look at how this move works into the company's broader strategy, why he thinks it was a great sale for Novartis, and what he thinks of the stock going forward.
Follow David on Twitter @MotleyDavid.
Alison Southwick has no position in any stocks mentioned. David Williamson owns shares of Novartis. The Motley Fool recommends ImmunoGen and Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.